-

06:51:23 PM

OCUP Stock News

OCUP - Ocuphire Pharma Inc

11/23/21 9:00 AM

Nasdaq : OCUP

clinical triallow float

Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)

Ocuphire Pharma, Inc.

RHEA-AI

positive

11/12/21 7:00 AM

Nasdaq : OCUP

earningslow float

Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update

On Track to Initiate Additional Phase 3 FDA Registration Trials for Nyxol ® Eye Drops in Reversal of Mydriasis (RM) in 4Q21 and Presbyopia in 1H22 Three Clinical Trial Data Readouts Expected in Early 2022 for Nyxol in Night Vision Disturbance, RM, and RM for Pediatric Patients Planned NDA

RHEA-AI

neutral

11/01/21 9:30 AM

Nasdaq : OCUP

conferencesclinical triallow float

Ocuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO Meeting

FDA Approves First Pharmaceutical Therapy to Treat Presbyopia; Nyxol on Track to Start Phase 3 Presbyopia Trials in First Half of 2022 Ocuphire Uniquely Positioned in Developing Late-Stage Innovative Therapies for Retinal Disease and Presbyopia FARMINGTON HILLS, Mich., Nov. 01, 2021 (GLOBE

RHEA-AI

very positive

10/07/21 7:00 AM

Nasdaq : OCUP

low float

Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases

New Review Publications Underscore the Role of the APE1/Ref-1 Protein in Multiple Pro-angiogenic Pathways Associated with Neovascular Eye Disease Including Diabetic Retinal Diseases and Age-Related Macular Degeneration Ocuphire’s Phase 2 ZETA-1Trial Evaluating APX3330 (an Oral Ref-1 Inhibitor) for

RHEA-AI

negative

10/01/21 8:49 AM

Nasdaq : OCUP

clinical triallow float

Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meeting

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that its clinical-stage, novel

RHEA-AI

neutral

09/27/21 7:00 AM

Nasdaq : OCUP

low float

Ocuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall

Ocuphire Pharma,

RHEA-AI

neutral

09/03/21 5:00 PM

Nasdaq : OCUP

low float

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire’s Inducement Plan as a material

RHEA-AI

neutral

09/02/21 7:00 AM

Nasdaq : OCUP

low float

Ocuphire Pharma Presenting at Four Conferences in September

Euro Forums 2021 Virtual Retina Forum on September 8, 2021 HC Wainwright Virtual 23 rd Annual Global Investment Conference on September 13-15, 2021 Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit on September 20-23, 2021 Cantor Virtual Global Healthcare Conference on September

RHEA-AI

neutral

08/12/21 7:00 AM

Nasdaq : OCUP

earningslow float

Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update

Continued Momentum in Nyxol ® Programs with Announcement of Positive Top-Line Results from VEGA-1 Phase 2 Trial in Presbyopia Nyxol plus Low-Dose Pilocarpine Phase 2 Trial Results Show Potential for Best-in-Class Presbyopia Drug Profile in Data Presentations at 2021 ASCRS Meeting $24M Cash Balance

RHEA-AI

neutral

08/06/21 7:30 AM

Nasdaq : OCUP

low float

Ocuphire Pharma Presenting at Two Conferences in August

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic

RHEA-AI

neutral

OCUP Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.ocuphire.com
CeoDouglas Swirsky
Security nameOcuphire Pharma Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees5
Tags
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address15245 Shady Grove Rd Ste 455
StateMaryland
CityRockville
Zip20850-7203
CountryUS
Phone12402685300

OCUP Description:

Ocuphire is a publicly traded, clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline currently includes two small- molecule product candidates targeting front and back of the eye indications. The company's lead product candidate, Nyxol® Eye Drops, is a once-dailypreservative-free eye drop formulation of phentolamine mesylate, a non-selectivealpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal pharmacologically-induced mydriasis (RM), and presbyopia. Ocuphire's second product candidate, APX3330, is a twice- a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME). Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia. APX3330 is entering Phase 2 clinical development for DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation and commercialization of drugs in key global markets.